TEMPE, Ariz.--(BUSINESS WIRE)--Align Technology, Inc. (NASDAQ: ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign System of clear aligners, iTeroâ"¢ intraoral scanners, and exocadâ"¢ CAD/CAM software for digital orthodontics and restorative dentistry, today announced its collaboration with the University of Bern on Switzerland's first Swiss Oral Health Study – an epidemiological initiative led by Professor Dr. Hendrik Meyer-Lückel, director of the Clinic for C ...

Wealth Enhancement Advisory Services LLC increased its stake in Align Technology, Inc. (NASDAQ:ALGN – Free Report) by 38.9% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 15,551 shares of the medical equipment provider’s stock after acquiring an additional 4,359 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in Align Technology were worth $2,029,000 at the end of the most recent quarter. Get Align Techn ...

Giverny Capital Asset Management, LLC, an investment management company, recently published its fourth-quarter 2025 investor letter. A copy of the same can be downloaded here. The Portfolio returned 0.01% compared to 2.66% for the S&P 500. YTD, the fund returned 12.58% compared to 17.88% for the Index. The firm faced a challenging fourth quarter and calendar year, despite solid appreciation. The outperformance of a few large technology companies has negatively impacted performance, given the portfolio's und ...

Core Viewpoint Align Technology, Inc. (ALGN) is expected to report its fourth-quarter 2025 results on February 4, with positive growth anticipated in both revenues and earnings per share (EPS) compared to the previous year. Group 1: Earnings and Revenue Estimates - The Zacks Consensus Estimate for fourth-quarter revenues is $1.03 billion, indicating a 3.9% growth from the previous year [2] - The Zacks Consensus Estimate for earnings is $2.99 per share, reflecting a 22.5% increase from the year-ago figures [2] - Earnings estimates have remained unchanged at $2.99 per share over the past 60 days [3] Group 2: Factors Influencing Q4 Performance - The Clear Aligner segment is expected to benefit from increased volumes, particularly in the EMEA, APAC, and Latin American regions, with growth driven by orthodontists and general dentist channels [4] - Strong contributions are anticipated from products like Invisalign First and DSP touch-up cases, along with the rollout of the Invisalign System with mandibular advancement in Thailand and the Philippines [5] - Recent innovations in treatment planning tools, such as the ClinCheck Live Plan, are expected to enhance operational efficiency and positively impact revenues [6] Group 3: Segment Performance - Clear Aligner revenues are projected to grow by 3.9% year-over-year [7] - The Imaging Systems & CAD/CAM Services segment is likely to see revenue growth from increased scanner services and iTero CAD/CAM sales, with strong performance in scanner leases [8][9] - Recent product innovations within the iTero Digital Solutions ecosystem are expected to resonate well with customers, further driving revenue growth [10] Group 4: Earnings ESP and Zacks Rank - Align Technology has an Earnings ESP of -1.62%, indicating a lower chance of beating estimates [12] - The company currently holds a Zacks Rank of 2 (Buy), suggesting a favorable outlook compared to other stocks [13]

The Zacks Medical - Dental Supplies industry in the Medical sector is likely to continue its upward momentum in 2026, backed by persistent innovation, an aging population with increasing healthcare needs and normalized orders following significant destocking since COVID-19.In 2026, the industry is likely to see continued adoption of digital services and AI-enabled assessment tools that enhance patient experience and reduce administrative burdens for physicians. These services support faster response times t ...

It’s been around three years since the first time I covered Align Technology, Inc. ( ALGN ). At that time, I gave the company a Strong Sell rating, and said to brace for disappointment. In those 1091MSc in Finance. Long-term horizon investor mostly with 5-10 year horizon. I like to keep investing simple. I believe a portfolio should consist of a mix of growth, value, and dividend-paying stocks but usually end up looking for value more than anything. I also sell options from time to time.Analyst’s Disclosure ...

Core Viewpoint - The analysis of Align Technology, Inc. (ALGN) indicates a negative outlook, with a previous recommendation of Strong Sell due to anticipated disappointments in performance [1]. Company Analysis - Align Technology has been under scrutiny for approximately three years, with the initial assessment predicting challenges ahead [1]. - The analyst emphasizes a long-term investment horizon of 5-10 years, suggesting a preference for a balanced portfolio that includes growth, value, and dividend-paying stocks, although there is a stronger inclination towards value stocks [1].

Core Insights - A significant majority, four in five workers, believe that artificial intelligence (AI) will impact their daily tasks in the workplace, indicating a strong perception of AI's influence on job functions [1] Group 1: Worker Sentiment - Gen Z workers are particularly concerned about the increasing reliance on AI chatbots and automation in their workplaces, highlighting a generational divide in attitudes towards AI [1]

TEMPE, Ariz.--(BUSINESS WIRE)--Align Technology, Inc. (NASDAQ: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocadâ"¢ CAD/CAM software for digital orthodontics and restorative dentistry, today announced a new initiative with the Canadian Foundation for the Advancement of Orthodontics (CFAO). Under this initiative, Align has committed to support Invisalign treatment for 30 eligible pati. ...

Company Overview - Align Technology, Inc. (ALGN) has a market capitalization of $11.2 billion and specializes in developing and providing Invisalign clear aligners, Vivera retainers, and iTero intraoral scanners and services globally [1] Financial Performance - The company is expected to announce its fiscal Q4 2025 results on February 4, with analysts predicting earnings of $2.47 per share, reflecting a 26% increase from $1.96 per share in the same quarter last year [2] - For fiscal 2025, analysts forecast an EPS of $8.18, which represents a 16.7% increase from $7.01 in fiscal 2024 [3] - Following the Q3 2025 results on October 29, ALGN shares rose by 4.9%, with adjusted EPS reported at $2.61 and revenue at $995.7 million, surpassing consensus estimates [5] Market Performance - Over the past 52 weeks, ALGN stock has declined by 22.5%, underperforming the S&P 500 Index, which rose by 16.2%, and the State Street Health Care Select Sector SPDR ETF, which returned 13.3% [4] Analyst Sentiment - The consensus rating for ALGN stock is "Moderate Buy," with 15 analysts providing coverage: eight rated it as "Strong Buy," six as "Hold," and one as "Moderate Sell" [6] - The average analyst price target for ALGN is $171.38, indicating a potential upside of 2.2% from current levels [6]